Automatic conformal prescription of very selective saturation bands for in vivo 1H-MRSI of the prostate

NMR in Biomedicine

Volumn 25, Issue 4, 2012, Pages 643-653

  Venugopal, N ^a,b,c   Mccurdy, B ^a,b   Hovdebo, J ^c   Al Mehairi, S ^d   Alamri, A ^d   Sandhu, G S ^d   Sivalingam, S ^d   Drachenberg, D ^d   Ryner, L ^a,c  

^a UNIVERSITY OF MANITOBA   (Canada)

^b CANCERCARE MANITOBA   (Canada)

^c NATIONAL RESEARCH COUNCIL CANADA   (Canada)

^d UNIVERSITY OF MANITOBA   (Canada)

Author keywords

Conformal voxel; LCModel; Lipid contamination; Lipid suppression; Magnetic resonance spectroscopic imaging; Prostate cancer; Short TE

Indexed keywords

AUTOMATION; BENCHMARKING; CRAMER-RAO BOUNDS; DISEASES; IMAGE SEGMENTATION; LIPIDS; MAGNETIC RESONANCE; MAGNETISM; UROLOGY;

CONFORMAL VOXEL; LCMODEL; LIPID CONTAMINATIONS; LIPID SUPPRESSIONS; MAGNETIC RESONANCE SPECTROSCOPIC IMAGING; PROSTATE CANCERS; SHORT TE;

MAGNETIC RESONANCE SPECTROSCOPY;

LIPID;

ADULT; AGED; ARTICLE; CONFORMAL VOXEL MAGNETIC RESONANCE SPECTROSCOPY; CONTROLLED STUDY; HUMAN; MALE; NORMAL HUMAN; ORGAN SIZE; PRIORITY JOURNAL; PROSTATE; PROTON NUCLEAR MAGNETIC RESONANCE; THREE DIMENSIONAL IMAGING;

EID: 84858867240     PISSN: 09523480     EISSN: 10991492     Source Type: Journal    
DOI: 10.1002/nbm.1780     Document Type: Article

References (58)

1. Kurhanewicz J, Thomas A, Jajodia P, Weiner MW, James TL, Vigneron DB, Narayan P. 31P spectroscopy of the human prostate gland in vivo using a transrectal probe. Magn. Reson. Med. 1991; 22: 404-413.
2. Heerschap A, Jager GJ, van der Graaf M, Barentsz JO, Ruijs SH. Proton MR spectroscopy of the normal human prostate with an endorectal coil and a double spin-echo pulse sequence. Magn Reson Med. 1997; 37(2): 204-213.
3. Rajesh A, Coakley FV, Kurhanewicz J. 3D MR spectroscopic imaging in the evaluation of prostate cancer. Clin. Radiol. 2007; 62: 921-929.
4. Scheenen TW, Heijmink SW, Roell SA, Hulsbergen-Van de Kaa CA, Knipscheer BC, Witjes JA, Barentsz JO, Heerschap A. Three-dimensional proton MR spectroscopy of human prostate at 3T without endorectal coil: feasibility. Radiology 2007; 245: 507-516.
5. Kurhanewicz J, Vigneron DB. Advances in MR Spectroscopy of the Prostate. Magn. Reson. Imaging Clin. N. Am. 2008; 16: 697-710.
6. Westphalen AC, McKenna DA, Kurhanewicz J, Coakley FV. Role of magnetic resonance imaging and magnetic resonance spectroscopic imaging before and after radiotherapy for prostate cancer. J. Endourol. 2008; 22: 789-794.
7. Scheenen TW, Klomp DW, Roll SA, Futterer JJ, Barentsz JO, Heerschap A. Fast acquisition-weighted three-dimensional proton MR spectroscopic imaging of the human prostate. Magn. Reson. Med. 2004; 52: 80-88.
8. Reinsberg SA, Payne GS, Riches SF, Ashley S, Brewster JM, Morgan VA, de Souza NM. Combined use of diffusion-weighted MRI and 1H MR spectroscopy to increase accuracy in prostate cancer detection. AJR. Am. J. Roentgenol 2007; 188: 91-98.
9. Jagannathan NR, Kumar V, Kumar R, Thulkar S. Role of magnetic resonance methods in the evaluation of prostate cancer: an Indian perspective. Magma 2008; 21: 393-407.
10. Sciarra A, Panebianco V, Ciccariello M, Salciccia S, Gentilucci A, Lisi D, Passariello R, Gentile V, Di Silverio F. Complete response to the combination therapy with androgen blockade and somatostatin analogue in a patient with advanced prostate cancer: magnetic resonance imaging with 1H-spectroscopy. Eur. Urol. 2008; 53: 652-655.
11. Noworolski SM, Henry RG, Vigneron DB, Kurhanewicz J. Dynamic contrast-enhanced MRI in normal and abnormal prostate tissues as defined by biopsy, MRI, and 3D MRSI. Magn. Reson. Med. 2005; 53: 249-255.
12. Coakley FV, Chen I, Qayyum A, Westphalen AC, Carroll PR, Hricak H, Chen MH, Kurhanewicz J. Validity of prostate-specific antigen as a tumour marker in men with prostate cancer managed by watchful-waiting: correlation with findings at serial endorectal magnetic resonance imaging and spectroscopic imaging. BJU Int. 2007; 99: 41-45.
13. Kurhanewicz J, Swanson MG, Nelson SJ, Vigneron DB. Combined magnetic resonance imaging and spectroscopic imaging approach to molecular imaging of prostate cancer. J. Magn. Reson. Imaging 2002; 16: 451-463.
14. Swanson MG, Vigneron DB, Tabatabai ZL, Males RG, Schmitt L, Carroll PR, James JK, Hurd RE, Kurhanewicz J. Proton HR-MAS spectroscopy and quantitative pathologic analysis of MRI/3D-MRSI-targeted postsurgical prostate tissues. Magn. Reson. Med. 2003; 50: 944-954.
15. Wang XZ, Wang B, Gao ZQ, Liu JG, Liu ZQ, Niu QL, Sun ZK, Yuan YX. 1H-MRSI of prostate cancer: The relationship between metabolite ratio and tumor proliferation. Eur. J. Radiol. 2008; 73: 345-351.
16. Kurhanewicz J, Vigneron D, Carroll P, Coakley F. Multiparametric magnetic resonance imaging in prostate cancer: present and future. Curr. Opin. Urol. 2008; 18: 71-77.
17. Westphalen AC, Coakley FV, Qayyum A, Swanson M, Simko JP, Lu Y, Zhao S, Carroll PR, Yeh BM, Kurhanewicz J. Peripheral zone prostate cancer: accuracy of different interpretative approaches with MR and MR spectroscopic imaging. Radiology 2008; 246: 177-184.
18. Umbehr M, Bachmann LM, Held U, Kessler TM, Sulser T, Weishaupt D, Kurhanewicz J, Steurer J. Combined magnetic resonance imaging and magnetic resonance spectroscopy imaging in the diagnosis of prostate cancer: a systematic review and meta-analysis. Eur. Urol. 2009; 55: 575-590.
19. Kurhanewicz J, Vigneron DB, Hricak H, Narayan P, Carroll P, Nelson SJ. Three-dimensional H-1 MR spectroscopic imaging of the in situ human prostate with high (0.24-0.7-cm3) spatial resolution. Radiology 1996; 198: 795-805.
20. Golder W. Magnetic resonance spectroscopy in clinical oncology. Onkologie 2004; 27: 304-309.
21. Scheidler J, Hricak H, Vigneron DB, Yu KK, Sokolov DL, Huang LR, Zaloudek CJ, Nelson SJ, Carroll PR, Kurhanewicz J. Prostate cancer: localization with three-dimensional proton MR spectroscopic imaging--clinicopathologic study. Radiology 1999; 213: 473-480.
22. Kim Y, Hsu IC, Lessard E, Kurhanewicz J, Noworolski SM, Pouliot J. Class solution in inverse planned HDR prostate brachytherapy for dose escalation of DIL defined by combined MRI/MRSI. Radiother Oncol. 2008; 88: 148-155.
23. Pickett B, Kurhanewicz J, Pouliot J, Weinberg V, Shinohara K, Coakley F, Roach M 3rd. Three-dimensional conformal external beam radiotherapy compared with permanent prostate implantation in low-risk prostate cancer based on endorectal magnetic resonance spectroscopy imaging and prostate-specific antigen level. Int. J. Radiat. Oncol. Biol. Phys. 2006; 65: 65-72.
24. Payne GS, Leach MO. Applications of magnetic resonance spectroscopy in radiotherapy treatment planning. Br. J. Radiol. 2006; 79Spec No 1: S16-S26.
25. Casciani E, Gualdi GF. Prostate cancer: value of magnetic resonance spectroscopy 3D chemical shift imaging. Abdom. Imaging 2006; 31: 490-499.
26. Casciani E, Polettini E, Bertini L, Masselli G, Emiliozzi P, Amini M, Pansadoro V, Gualdi GF. Contribution of the MR spectroscopic imaging in the diagnosis of prostate cancer in the peripheral zone. Abdom. Imaging 2007; 32: 796-802.
27. Sciarra A, Panebianco V, Salciccia S, Osimani M, Lisi D, Ciccariello M, Passariello R, Di Silverio F, Gentile V. Role of dynamic contrast-enhanced magnetic resonance (MR) imaging and proton MR spectroscopic imaging in the detection of local recurrence after radical prostatectomy for prostate cancer. Eur. Urol. 2008; 54: 589-600.
28. Qayyum A, Coakley FV, Lu Y, Olpin JD, Wu L, Yeh BM, Carroll PR, Kurhanewicz J. Organ-confined prostate cancer: effect of prior transrectal biopsy on endorectal MRI and MR spectroscopic imaging. AJR Am. J. Roentgenol. 2004; 183: 1079-1083.
29. Tran TK, Vigneron DB, Sailasuta N, Tropp J, Le Roux P, Kurhanewicz J, Nelson S, Hurd R. Very selective suppression pulses for clinical MRSI studies of brain and prostate cancer. Magn. Reson. Med. 2000; 43: 23-33.
30. Schricker AA, Pauly JM, Kurhanewicz J, Swanson MG, Vigneron DB. Dualband spectral-spatial RF pulses for prostate MR spectroscopic imaging. Magn. Reson. Med. 2001; 46: 1079-1087.
31. Star-Lac J, Nelson SJ, Kurhanewicz J, Huang LR, Vigneron DB. Improved water and lipid suppression for 3D Author: please confirm that all abbreviations are now correct CSI using RF band selective inversion with gradient dephasing (basing). Magn. Reson. Med. 1997; 38: 311-321.
32. Mescher M, Merkle H, Kirsch J, Garwood M, Gruetter R. Simultaneous in vivo spectral editing and water suppression. NMR Biomed. 1998; 11: 266-272.
33. Singh S, Rutt BK, Mark Henkelman R. Projection presaturation: A fast and accurate technique for multidimensional spatial localization. J. Magn. Reson 1990; 87: 567-583.
34. Chen YJ, Rachamadugu S, Fernandez EJ. Three dimensional outer volume suppression for short echo time in vivo 1H spectroscopic imaging in rat brain. Magn. Reson. Imaging 1997; 15: 839-845.
35. Chu A, Alger JR, Moore GJ, Posse S. Proton echo-planar spectroscopic imaging with highly effective outer volume suppression using combined presaturation and spatially selective echo dephasing. Magn. Reson. Med. 2003; 49: 817-821.
36. Ryner LN, Westmacott G, Latta P, Davison N, inventors; National Research Council of Canada, Ottawa (CA), assignee. Magnetic Resonance Spectroscopy using a Conformal Voxel, Ottawa, Canada, U.S. Patent 2008.
37. Choi H, Ma J. Use of perfluorocarbon compound in the endorectal coil to improve MR spectroscopy of the prostate. AJR Am. J. Roentgenol. 2008; 190: 1055-1059.
38. Hovdebo J, Ryner L. An improved method for automatic placement of spatial saturation planes in MR spectroscopy. Proceedings of the 17th Annual Meeting ISMRM, Hawaii, 2009; 2376.
39. Venugopal N, McCurdy BMC, Ryner L. Improved prostate MRSI employing a conformal voxel technique. Proceedings of the 16th Annual Meeting ISMRM, Toronto, 2008; 2767.
40. Males RG, Vigneron DB, Star-Lack J, Falbo SC, Nelson SJ, Hricak H, Kurhanewicz J. Clinical application of BASING and spectral/spatial water and lipid suppression pulses for prostate cancer staging and localization by in vivo 3D 1H magnetic resonance spectroscopic imaging. Magn. Reson. Med. 2000; 43: 17-22.
41. Barber CB, Dobkin DP, Huhdanpaa H. The quickhull algorithm for convex hulls. ACM Trans. Math. Softw. 1996; 22: 469-483.
42. Garland M, Heckbert PS. Surface simplification using quadric error metrics. Proceedings of the 24th Annual Conference on Computer Graphics and Interactive Techniques. ACM Press/Addison-Wesley Publishing Co., New York, NY, USA, 1997.
43. Bottomley PA, Foster TH, Argersinger RE, Pfeifer LM. A review of normal tissue hydrogen NMR relaxation times and relaxation mechanisms from 1-100MHz: dependence on tissue type, NMR frequency, temperature, species, excision, and age. Med. Phys. 1984; 11: 425-448.
44. Jung JA, Coakley FV, Vigneron DB, Swanson MG, Qayyum A, Weinberg V, Jones KD, Carroll PR, Kurhanewicz J. Prostate depiction at endorectal MR spectroscopic imaging: investigation of a standardized evaluation system. Radiology 2004; 233: 701-708.
45. Mountford C. Magnetic resonance imaging and spectroscopy of the prostate. Magma 2008; 21: 369-370.
46. Crehange G, Parfait S, Liegard M, Maingon P, Ben Salem D, Cochet A, Funes de la Vega M, Cormier L, Bonnetain F, Mirjolet C, Brunotte F, Walker PM. Tumor volume and metabolism of prostate cancer determined by proton magnetic resonance spectroscopic imaging at 3T without endorectal coil reveal potential clinical implications in the context of radiation oncology. Int. J. Radiat. Oncol. Biol. Phys. (in press).
47. Weinreb JC, Blume JD, Coakley FV, Wheeler TM, Cormack JB, Sotto CK, Cho H, Kawashima A, Tempany-Afdhal CM, Macura KJ, Rosen M, Gerst SR, Kurhanewicz J. Prostate cancer: sextant localization at MR imaging and MR spectroscopic imaging before prostatectomy-results of ACRIN prospective multi-institutional clinicopathologic study. Radiology 2009; 251: 122-133.
48. Martinez-Ramon M, Gallardo-Antolin A, Cid-Sueiro J, Heileman GL, Yung KT, Zheng W, Zhao C, Posse S. Automatic placement of outer volume suppression slices in MR spectroscopic imaging of the human brain. Magn. Reson. Med. 2010; 63: 592-600.
49. Ozhinsky E, Vigneron DB, Nelson SJ. Improved spatial coverage for brain 3D PRESS MRSI by automatic placement of outer-volume suppression saturation bands. J. Magn. Reson. Imaging 2011; 33: 792-802.
50. McLean MA, Barrett T, Gnanapragasam VJ, Priest AN, Joubert I, Lomas DJ, Neal DE, Griffiths JR, Sala E. Prostate cancer metabolite quantification relative to water in (1)H-MRSI in vivo at 3 Tesla. Magn. Reson. Med. 2010 (in press).
51. Klomp DW, Bitz AK, Heerschap A, Scheenen TW. Proton spectroscopic imaging of the human prostate at 7T. NMR Biomed. 2009; 22: 495-501.
52. Klomp DW, Scheenen TW, Arteaga CS, van Asten J, Boer VO, Luijten PR. Detection of fully refocused polyamine spins in prostate cancer at 7T. NMR Biomed. 2011; 24(3): 299-306.
53. Scheenen TW, Futterer J, Weiland E, van Hecke P, Lemort M, Zechmann C, Schlemmer HP, Broome D, Villeirs G, Lu J, Barentsz J, Roell S, Heerschap A. Discriminating cancer from noncancer tissue in the prostate by 3-dimensional proton magnetic resonance spectroscopic imaging: a prospective multicenter validation study. Invest. Radiol. 2010; 46: 25-33.
54. Sciarra A, Panebianco V, Ciccariello M, Salciccia S, Lisi D, Osimani M, Alfarone A, Gentilucci A, Parente U, Passariello R, Gentile V. Magnetic resonance spectroscopic imaging (1H-MRSI) and dynamic contrast-enhanced magnetic resonance (DCE-MRI): pattern changes from inflammation to prostate cancer. Cancer Invest. 2010; 28: 424-432.
55. Yakar D, Heijmink SW, Hulsbergen-van de Kaa CA, Huisman H, Barentsz JO, Futterer JJ, Scheenen TW. Initial results of 3-dimensional 1H-magnetic resonance spectroscopic imaging in the localization of prostate cancer at 3 Tesla: should we use an endorectal coil? Invest. Radiol. 2011 (in press).
56. Venugopal N, McCurdy B, Mehairi SA, Alamri A, Sandhu GS, Drachenberg D, Ryner L. Short echo time in vivo prostate MRSI. Proceedings of the 18th Annual Meeting ISMRM, Stockholm, Sweden, 2010; 2807.
57. Henning A, Schar M, Schulte RF, Wilm B, Pruessmann KP, Boesiger P. SELOVS: brain MRSI localization based on highly selective T1- and B1- insensitive outer-volume suppression at 3T. Magn. Reson. Med. 2008; 59: 40-51.
58. Henning A, Fuchs A, Murdoch JB, Boesiger P. Slice-selective FID acquisition, localized by outer volume suppression (FIDLOVS) for (1)H-MRSI of the human brain at 7T with minimal signal loss. NMR Biomed. 2009; 22: 683-696.